image
Real Estate - REIT - Retail - NYSE - US
$ 71.97
-0.125 %
$ 7.92 B
Market Cap
40.66
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ADC stock under the worst case scenario is HIDDEN Compared to the current market price of 72 USD, Agree Realty Corporation is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ADC stock under the base case scenario is HIDDEN Compared to the current market price of 72 USD, Agree Realty Corporation is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ADC stock under the best case scenario is HIDDEN Compared to the current market price of 72 USD, Agree Realty Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ADC

image
$80.0$80.0$78.0$78.0$76.0$76.0$74.0$74.0$72.0$72.0$70.0$70.0$68.0$68.0$66.0$66.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
617 M REVENUE
14.81%
302 M OPERATING INCOME
18.81%
190 M NET INCOME
11.31%
432 M OPERATING CASH FLOW
10.31%
-885 M INVESTING CASH FLOW
30.56%
445 M FINANCING CASH FLOW
-48.76%
169 M REVENUE
5.24%
78.7 M OPERATING INCOME
4.46%
47.1 M NET INCOME
3.90%
127 M OPERATING CASH FLOW
38.58%
-381 M INVESTING CASH FLOW
-9.33%
259 M FINANCING CASH FLOW
3.54%
Balance Sheet Agree Realty Corporation
image
Current Assets 113 M
Cash & Short-Term Investments 6.4 M
Receivables 106 M
Other Current Assets 0
Non-Current Assets 8.37 B
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 8.37 B
98.67 %Total Assets$8.5b
Current Liabilities 144 M
Accounts Payable 116 M
Short-Term Debt 0
Other Current Liabilities 27.8 M
Non-Current Liabilities 2.83 B
Long-Term Debt 2.78 B
Other Non-Current Liabilities 51 M
3.91 %93.44 %Total Liabilities$3.0b
EFFICIENCY
Earnings Waterfall Agree Realty Corporation
image
Revenue 617 M
Cost Of Revenue 74.8 M
Gross Profit 542 M
Operating Expenses 240 M
Operating Income 302 M
Other Expenses 112 M
Net Income 190 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00617m(75m)542m(240m)302m(112m)190mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
87.87% GROSS MARGIN
87.87%
48.98% OPERATING MARGIN
48.98%
30.66% NET MARGIN
30.66%
3.43% ROE
3.43%
2.23% ROA
2.23%
3.54% ROIC
3.54%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Agree Realty Corporation
image
450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 190 M
Depreciation & Amortization 240 M
Capital Expenditures 0
Stock-Based Compensation 10.8 M
Change in Working Capital -2.57 M
Others -11.1 M
Free Cash Flow 432 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Agree Realty Corporation
image
Wall Street analysts predict an average 1-year price target for ADC of $78.9 , with forecasts ranging from a low of $74 to a high of $82.5 .
ADC Lowest Price Target Wall Street Target
74 USD 2.82%
ADC Average Price Target Wall Street Target
78.9 USD 9.65%
ADC Highest Price Target Wall Street Target
82.5 USD 14.63%
Price
Max Price Target
Min Price Target
Average Price Target
84848282808078787676747472727070686866666464Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
1.01% DIVIDEND YIELD
0.256 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.5002.5002.0002.0001.5001.5001.0001.0000.5000.5000.0000.0000.450.4650.4950.520.5550.5850.2070.2070.2070.2270.2270.2270.240.240.240.2470.2470.2470.2530.2530.2530.4650.480.5050.540.570.60.2170.2170.2170.2340.2340.2340.2430.2430.2430.250.250.250.2560.2560.2560.4650.480.5050.540.570.60.2170.2170.2170.2340.2340.2340.2430.2430.2430.250.250.250.4651.850.4951.920.522.030.5551.620.5852.250.622.380.2271.250.2270.870.2270.870.240.920.240.940.240.940.2470.960.2470.970.2470.970.2530.990.2531.000.2531.000.500.510.510.262015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Agree Realty Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
2.75 M USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
2.13 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
2 Top Dividend Stocks to Buy in July There are different ways to use dividends when it comes to selecting investments. Often, dividend investors focus all their attention on the highest-yielding stocks. fool.com - 1 day ago
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy HONG KONG , July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispecific ADC to enter clinical trials. prnewswire.com - 4 days ago
Sell Alert: 2 REITs Getting Pricey Overall, REITs remain deeply undervalued. But some exceptions are getting pricey. I highlight 2 REITs that I sold recently. seekingalpha.com - 5 days ago
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan LAUSANNE, Switzerland , July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. prnewswire.com - 6 days ago
Agree Realty Announces Second Quarter 2025 Earnings Release Date and Conference Call Information ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2025 operating results after the market closes on Thursday, July 31, 2025. A conference call to discuss the Company's operating results is scheduled for Friday, August 1, 2025 at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871   International (646) 307-1963  . businesswire.com - 1 week ago
2 High-Yield High-Conviction Blue-Chip Buys For H2 2025 High yield, high conviction blue-chip stocks are invaluable for both income and value investors. I share two of my top picks for H2 2025. I also share some of the risks facing them. seekingalpha.com - 1 week ago
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms SAN FRANCISCO and SUZHOU, China , June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. prnewswire.com - 1 week ago
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab). globenewswire.com - 1 week ago
How To Play REITs From Here REITs are attractive for income-focused investors, especially retirees, due to required high payouts and current undervaluation from elevated interest rates. Interest rates heavily influence REIT performance; while rates remain high, this is an opportunity to accumulate quality REITs for long-term gains. I highlight Agree Realty, NNN REIT, and Alexandria Real Estate Equities as fundamentally sound picks with double-digit upside potential over the next 1–2 years. seekingalpha.com - 1 week ago
Dividend Stocks I Would Bet My Retirement On Building a portfolio of dividend machines is a great way to fund a retirement. I share two types of stocks that I would bet my retirement on. I share some of my top dividend income picks of the moment. seekingalpha.com - 1 week ago
Five Popular Stocks Insiders Have Been Aggressively Buying We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable. 247wallst.com - 1 week ago
Why AI Makes REITs More Valuable AI adoption will drive long-term value for REITs by boosting efficiency, reducing costs, and expanding profit margins, ultimately raising FFO and fair valuations. Management-intensive REIT sectors—like multifamily, retail, tower infrastructure, and single-family rentals—stand to benefit most from AI-powered operational improvements. Smaller REITs may gain a competitive edge as AI tools help them operate more efficiently, potentially narrowing the gap with larger players. seekingalpha.com - 2 weeks ago
8. Profile Summary

Agree Realty Corporation ADC

image
COUNTRY US
INDUSTRY REIT - Retail
MARKET CAP $ 7.92 B
Dividend Yield 1.01%
Description Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.
Contact 70 East Long Lake Road, Royal Oak, MI, 48304 https://www.agreerealty.com
IPO Date April 15, 1994
Employees 75
Officers Mr. Reuben Goldman Treatman CPA Senior Director of Corporate Finance Mr. Josh Bratton Director of Development Mr. Larry Kaufman Chief Information Officer & Vice President of Continuous Improvement Ms. Danielle M. Spehar J.D. General Counsel Mr. Joel N. Agree J.D. President, Chief Executive Officer & Director Ms. Nicole Witteveen Chief Operating Officer Mr. Peter Coughenour Chief Financial Officer, Secretary & Investor Relations Professional Mr. Stephen Breslin Chief Accounting Officer Mr. Craig Erlich Chief Growth Officer Mr. Richard A. Agree Executive Chairman of the Board